COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions

Ryan C. Ungaro; Michael D. Kappelman; David T. Rubin; Jean Frederic Colombel

doi:10.1053/j.gastro.2020.12.042

COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions

Ryan C. Ungaro, Michael D. Kappelman, David T. Rubin, Jean Frederic Colombel

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Original language	English
Pages (from-to)	1447-1451
Number of pages	5
Journal	Gastroenterology
Volume	160
Issue number	5
DOIs	https://doi.org/10.1053/j.gastro.2020.12.042
State	Published - Apr 2021

Access to Document

10.1053/j.gastro.2020.12.042

Cite this

@article{8bdf91944c7d44d5a78b74c9406b65a2,

title = "COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions",

author = "Ungaro, {Ryan C.} and Kappelman, {Michael D.} and Rubin, {David T.} and Colombel, {Jean Frederic}",

note = "Funding Information: Funding RCU is supported by a Career Development Award from the National Institutes of Health ( K23KD111995-01A1 ). Funding Information: Funding RCU is supported by a Career Development Award from the National Institutes of Health (K23KD111995-01A1). Conflicts of interest The authors have made the following disclosures: RCU has served as a consultant and/or advisory board member for Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer and Takeda. He has received research support from AbbVie, Boehringer Ingelheim and Pfizer. MDK has consulted for Abbvie, Janssen, Pfizer, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. DTR has received grant support from Abbvie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, and Takeda; and has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Biomica, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, GlaxoSmithKline Services, Ichnos Sciences S.A., InDex Pharmaceuticals, Janssen Pharmaceuticals, Lilly, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development.",

year = "2021",

month = apr,

doi = "10.1053/j.gastro.2020.12.042",

language = "English",

volume = "160",

pages = "1447--1451",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "5",

}

TY - JOUR

T1 - COVID-19 and Inflammatory Bowel Disease

T2 - Lessons Learned, Practical Recommendations, and Unanswered Questions

AU - Ungaro, Ryan C.

AU - Kappelman, Michael D.

AU - Rubin, David T.

AU - Colombel, Jean Frederic

N1 - Funding Information: Funding RCU is supported by a Career Development Award from the National Institutes of Health ( K23KD111995-01A1 ). Funding Information: Funding RCU is supported by a Career Development Award from the National Institutes of Health (K23KD111995-01A1). Conflicts of interest The authors have made the following disclosures: RCU has served as a consultant and/or advisory board member for Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer and Takeda. He has received research support from AbbVie, Boehringer Ingelheim and Pfizer. MDK has consulted for Abbvie, Janssen, Pfizer, and Takeda, is a shareholder in Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, and Arenapharm. DTR has received grant support from Abbvie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire, and Takeda; and has served as a consultant for Abbvie, Abgenomics, Allergan Inc., Biomica, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene Corp/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, GlaxoSmithKline Services, Ichnos Sciences S.A., InDex Pharmaceuticals, Janssen Pharmaceuticals, Lilly, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Jean-Frederic Colombel has received research grants from AbbVie, Janssen Pharmaceuticals and Takeda; has received payment for lectures from AbbVie, Amgen, Allergan, Bristol-Myers Squibb Company, Ferring Pharmaceuticals, Shire, Takeda and Tillots; has received consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Gilead, Iterative Scopes, Ipsen, Immunic, lmtbio, Inotrem, Janssen Pharmaceuticals, Landos, LimmaTech Biologics AG, Medimmune, Merck, Novartis, O Mass, Otsuka, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development.

PY - 2021/4

Y1 - 2021/4

UR - http://www.scopus.com/inward/record.url?scp=85104159870&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2020.12.042

DO - 10.1053/j.gastro.2020.12.042

M3 - Article

C2 - 33387525

AN - SCOPUS:85104159870

SN - 0016-5085

VL - 160

SP - 1447

EP - 1451

JO - Gastroenterology

JF - Gastroenterology

IS - 5

ER -